Wealthstream Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$1.36M Buy
1,776
+202
+13% +$150K 0.2% 44
2025
Q2
$1.23M Buy
1,574
+255
+19% +$198K 0.2% 47
2025
Q1
$1.09M Buy
1,319
+49
+4% +$40.8K 0.2% 41
2024
Q4
$980K Sell
1,270
-62
-5% -$51.3K 0.18% 50
2024
Q3
$1.18M Buy
1,332
+54
+4% +$48.5K 0.21% 38
2024
Q2
$1.16M Sell
1,278
-6
-0.5% -$4.8K 0.42% 33
2024
Q1
$999K Sell
1,284
-392
-23% -$279K 0.38% 41
2023
Q4
$977K Buy
1,676
+766
+84% +$447K 0.4% 34
2023
Q3
$489K Buy
910
+87
+11% +$44.8K 0.25% 54
2023
Q2
$386K Buy
823
+44
+6% +$18.5K 0.2% 59
2023
Q1
$268K Buy
779
+45
+6% +$15.2K 0.16% 61
2022
Q4
$269K Sell
734
-6
-0.8% -$2.13K 0.18% 59
2022
Q3
$239K Buy
740
+32
+5% +$10.1K 0.26% 55
2022
Q2
$230K Buy
+708
New +$213K 0.23% 60

Other funds holding LLY

Wealthstream Advisors's LLY Position: Q3 2025 in Review

Wealthstream Advisors increased its Eli Lilly (LLY) stake by 13% in Q3 2025, buying an estimated $150K and bringing the position to 1,776 shares worth $1.36M. The position accounts for 0.2% of the portfolio, ranked #44.

Wealthstream Advisors first reported a position in LLY in Q2 2022 and has held it in 14 quarters since. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.

  • Wealthstream Advisors held 1,776 shares of Eli Lilly worth $1.36M as of Q3 2025.
  • Wealthstream Advisors bought 202 Eli Lilly shares in Q3 2025, an estimated $150K.
  • Eli Lilly made up 0.2% of Wealthstream Advisors's portfolio in Q3 2025, its #44 holding.
  • Wealthstream Advisors first reported a position in Eli Lilly in Q2 2022 and has held it in 14 quarters since.
  • 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.

Based on Wealthstream Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.